Literature DB >> 8275439

Factors influencing survival after resection of pancreatic cancer. A DNA analysis and a histomorphologic study.

T C Böttger1, S Störkel, S Wellek, M Stöckle, T Junginger.   

Abstract

BACKGROUND: The influence of DNA content on prognosis in stomach cancer has been investigated rarely, and the results are controversial.
METHOD: The prognostic relevance of the DNA content and histomorphologic parameters was evaluated in 41 patients after resection of pancreatic cancer.
RESULTS: In the univariate analysis, the DNA content, tumor size, lymph node status, tumor stage, nuclear grade, and type of resection had a statistically significant influence on the prognosis. No association was found between the DNA content and the histomorphologic features. Apart from the operative procedure, the DNA content was the strongest indicator of prognosis in the multivariate analysis.
CONCLUSIONS: Further investigations are necessary to find out if DNA analysis can be performed preoperatively on material obtained by fine-needle aspiration.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8275439     DOI: 10.1002/1097-0142(19940101)73:1<63::aid-cncr2820730113>3.0.co;2-p

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  Pathomorphological and histological prognostic factors in curatively resected ductal adenocarcinoma of the pancreas.

Authors:  W Meyer; C Jurowich; M Reichel; B Steinhäuser; P H Wünsch; C Gebhardt
Journal:  Surg Today       Date:  2000       Impact factor: 2.549

2.  Significance of proliferative activity and DNA ploidy in pancreatic cancer and chronic pancreatitis.

Authors:  H Loertzer; R Hinze; J Knolle; F W Rath; A Schmassmann
Journal:  Int J Pancreatol       Date:  1999-10

Review 3.  Intraoperative assessment of the Whipple resection specimen.

Authors:  Mahmoud A Khalifa
Journal:  J Clin Pathol       Date:  2007-03-16       Impact factor: 3.411

Review 4.  Current management of pancreatic carcinoma.

Authors:  K D Lillemoe
Journal:  Ann Surg       Date:  1995-02       Impact factor: 12.969

5.  Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience.

Authors:  C J Yeo; R A Abrams; L B Grochow; T A Sohn; S E Ord; R H Hruban; M L Zahurak; W C Dooley; J Coleman; P K Sauter; H A Pitt; K D Lillemoe; J L Cameron
Journal:  Ann Surg       Date:  1997-05       Impact factor: 12.969

6.  Molecular diagnosis of exocrine pancreatic cancer using a percutaneous technique.

Authors:  D B Evans; M L Frazier; C Charnsangavej; R L Katz; L Larry; J L Abbruzzese
Journal:  Ann Surg Oncol       Date:  1996-05       Impact factor: 5.344

7.  [DNA content of the tumor cell. A new prognostic parameter in hepatocellular carcinoma?].

Authors:  T Böttger; J Seifert; M Mörschel; K Lauer; T Junginger
Journal:  Langenbecks Arch Chir       Date:  1996

8.  Combined use of nuclear morphometry and DNA ploidy as prognostic indicators in nonresectable adenocarcinoma of the pancreas.

Authors:  S Linder; J Lindholm; U Falkmer; M Blåsjö; P Sundelin; A von Rosen
Journal:  Int J Pancreatol       Date:  1995-12

9.  Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients.

Authors:  C J Yeo; J L Cameron; K D Lillemoe; J V Sitzmann; R H Hruban; S N Goodman; W C Dooley; J Coleman; H A Pitt
Journal:  Ann Surg       Date:  1995-06       Impact factor: 12.969

10.  Evaluation of DNA ploidy in relation with established prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.

Authors:  Nikolas Tsavaris; Nicolaos Kavantzas; Kostantinos Tsigritis; Ioannis D Xynos; Nikitas Papadoniou; Andreas Lazaris; Christos Kosmas; George Agrogiannis; Anna Dokou; Evangelos Felekouras; Efstathios Antoniou; Aris Polyzos; John Sarantonis; Heracles Tsipras; Gavrilos Karatzas; Alexandros Papalambros; Efstratios S Patsouris
Journal:  BMC Cancer       Date:  2009-07-31       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.